# SHIELD II Clinical Investigation

> **NCT02468778** · NA · TERMINATED · sponsor: **Abbott Medical Devices** · enrollment: 54 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DEVICE:** HeartMate PHP
- **DEVICE:** Any Abiomed Impella® device approved for use in high-risk PCI

## Key facts

- **NCT ID:** NCT02468778
- **Lead sponsor:** Abbott Medical Devices
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-05-17
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Abbott has decided to discontinue our percutaneous heart pump (PHP) program and the SHIELD II trial because the product was not meeting the needs of the patients it was intended to serve.
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468778, "SHIELD II Clinical Investigation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02468778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*